Aug 2026· Critical reviews in clinical laboratory sciences· pp.
1-34
· 0 citations· 252 references
Medicine
TL;DR
Inflammatory biomarkers and epigenetic inflammation scores may support cancer risk stratification, early detection, prognostic assessment and treatment monitoring; however, most should be interpreted as complementary laboratory tools rather than stand-alone diagnostic tests, and clinical implementation requires standardized analytical platforms, harmonized cutoff values, demonstration of incremental utility and prospective validation.
Abstract
Chronic inflammation is now recognized as an important factor linking tissue damage to the development of cancer. Epidemiological studies have suggested that 20%-25% of cancers are related to chronic inflammation, as exemplified by chronic hepatitis B infection inducing hepatocellular carcinoma (HCC) or Helicobacter pylori infection inducing the development of gastric cancer. In chronic inflammation, an overexpression of signaling pathways such as NF-κB, JAK/STAT3, MAPK and NLRP3 at the molecular level leads to continuous upregulation of the secretion of pro-inflammatory cytokines and immune-metabolic reprogramming. These processes result in DNA damage, genetic mutations and epigenetic changes, promoting the initiation and progression of tumors. Interactions between pro-inflammatory cytokines and different types of cellular constituents reshape the tumor microenvironment (TME), leading to fibrosis, chaotic angiogenesis, and immune suppression-favoring further immune escape by tumors and perpetuating cancer stemness. Furthermore, through epigenetic as well as other molecular mechanisms, chronic inflammation fosters tumor drug resistance. So far, anti-inflammatory agents (e.g. anti-inflammatory drugs and natural bioactive compounds) as well as forms of dietary intervention have been associated with a reduced risk of cancer development in selected inflammation-associated settings, emphasizing that inflammation control may contribute to cancer prevention when supported by appropriate patient selection and clinical validation. In addition, new anti-inflammatory drug interventions targeting the IL-6/STAT3, NF-κB and NLRP3 pathways have shown good prospects for inhibiting tumors while modulating the immune microenvironment. Inflammatory biomarkers and epigenetic inflammation scores may support cancer risk stratification, early detection, prognostic assessment and treatment monitoring; however, most should be interpreted as complementary laboratory tools rather than stand-alone diagnostic tests, and their clinical implementation requires standardized analytical platforms, harmonized cutoff values, demonstration of incremental utility and prospective validation.
Obesity increases the risk and progression of at least 13 types of cancer. Although the epidemiologic links between excess adiposity and these cancers are well documented, the biological mechanisms linking obesity to carcinogenesis and tumor progression remain incompletely understood. White adipose tissue in obesity is...
Pritika Pandey, Jeb F. Struder, Erika T. Rezeli et al.· Frontiers in Oncology· 0 citations
Obesity, recognized as a significant global public health issue, has garnered widespread attention. The chronic systemic inflammatory state characteristic of obesity may act as a key pathophysiological factor in the development of obesity-related cancers. Based on a structured literature search of peer-reviewed databas...
Jia Meng, Xue-Kai Bao· Frontiers in Immunology· 0 citations
Chronic colitis is a major risk factor for colorectal cancer (CRC), particularly for colitis-associated colorectal cancer (CAC), where persistent inflammation drives the transition from mucosal injury to malignant transformation. Accumulating evidence indicates that gut microbiota dysbiosis, epithelial barrier disrupti...
Yi Lu, Xi-Xi Wang, C. Yin et al.· Molecular Biomedicine· 0 citations
Colorectal cancer (CRC) represents a major cause of cancer-associated morbidity and mortality worldwide, with significantly higher incidence and lethality in elderly individuals. Growing evidence implicates immunosenescence, the age-dependent functional decline of the immune system, as a key contributor to CRC initiati...
Current evidence on how the gut microbiota and inflammatory cytokines jointly regulate tumour development and therapeutic outcomes is summarized and therapeutic strategies that target microbial composition and inflammatory signalling are discussed.
Yan Liu, D. Zang, Jun Chen· Frontiers in Immunology· 0 citations
Through its mediation between inflammatory and immune pathways, the gut microbiota has proved to be a key regulator of cancer development, progression, and treatment response. Changes in microbial composition known as dysbiosis might facilitate chronic inflammation, immune dysregulation, and genomic instability, thereb...